Back

Exploring pathophysiological phenotyping and medical optimization in secondary tricuspid valve regurgitation prior to tricuspid valve edge to edge repair

13 May 2024 (10:00 - 10:45)
Organised by: Logo
Congress Presentation Part of: Valvular heart disease 2 Intervention HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Ippokratis Zarifis

Laiko University General Hospital, Athens (Greece)

5 More presentations in this session

Presentation thumbnail
Homozygous familial hypercholesterolemia surgical management and outcomes in up to 23 years follow up: a new Horizon for the Ross Procedure.
Professor D. Galzerano (Riyadh, SA)
Abstract Slides Video
Presentation thumbnail
Insights into ultrasound-guided femoral puncture in transcatheter aortic valve replacement: analyzing vascular complications and mortality rates
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Prognostic implications of left atrial volume index in patients with ventricular functional mitral regurgitation underwent transcatheter edge-to-edge repair
Doctor M. Maeda (Kumamoto, JP)
Abstract Slides Video
Presentation thumbnail
Impact of COAPT trial in patients with secondary mitral regurgitation submitted to MitraClip: an exploratory analysis of clinical outcomes in a tertiary care center
Doctor F. Barbas De Albuquerque (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Too little, too late: atrial secondary tricuspid regurgitation (A-STR) carries a better prognosis in early-stage heart failure, but not in late-stage
Doctor C. Bourg (Rennes, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Valvular heart disease 2

The Event

Event poster

Heart Failure 2024

13 May 2024 10:00 CET
You may be interested in
thumbnail
Congress Session
Who are the optimal candidates for tricuspid transcatheter edge-to-edge valve repair?
thumbnail
Congress Presentation
Secondary tricuspid regurgitation: from early identification to treatment
thumbnail
Congress Presentation
Tricuspid regurgitation and heart failure: focus on the optimal indication for intervention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources